AMYT 외환 뉴스
Amryt Pharma To Submit Formal Dispute Resolution Request For Oleogel-S10 NDA
Biopharmaceutical company Amryt Pharma plc (AMYT) announced Friday that the company plans to submit a Formal Dispute Resolution Request (FDRR) for the company's New Drug Application (NDA) for Oleogel-S10 (Filsuvez), for the treatment of the cutaneous manifestations of Dystrophic and Junctional Epidermolysis Bullosa (EB).
RTTNews
|
894 일 전
Amryt Pharma Says European Commission Oks Filsuvez For Dystrophic And Junctional EB
Biopharmaceutical company Amryt Pharma plc (AMYT) announced the European Commission (EC) approval of Filsuvez in the European Union (EU) for the treatment of partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients 6 months and older.
RTTNews
|
895 일 전
